EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Three Distinct Reporter Systems of Hepatitis E Virus and Their Utility as Drug Screening Platforms

Putu Prathiwi Primadharsini iD, Shigeo Nagashima iD, Takashi Nishiyama, Hiroaki Okamoto iD

Viruses · 2023

DOI: 10.3390/v15101989 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Viruses, 2023. Verfasst von Putu Prathiwi Primadharsini und 3 weiteren Autor:innen. Beteiligte Einrichtung: Division of Virology, Department of Infection and Immunity, Jichi Medical University School of Medicine, 3311-1 Yakushiji, Shimotsuke 329-0498, Tochi…. Hauptthemen laut MEDLINE: Hepatitis E virus, Hepatitis E. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 106 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Japan Society for the Promotion of Science, Japan Agency for Medical Research and Development.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The hepatitis E virus (HEV) is increasingly acknowledged as the primary cause of acute hepatitis. While most HEV infections are self-limiting, cases of chronic infection and fulminant hepatitis necessitate the administration of anti-HEV medications. However, there is a lack of specific antiviral drugs designed for HEV, and the currently available drug (ribavirin) has been associated with significant adverse effects. The development of innovative antiviral drugs involves targeting distinct steps within the viral life cycle: the early step (attachment and internalization), middle step (translation and RNA replication), and late step (virus particle formation and virion release). We recently established three HEV reporter systems, each covering one or two of these steps. Using these reporter systems, we identified various potential drug candidates that target different steps of the HEV life cycle. Through rigorous in vitro testing using our robust cell culture system with the genotype 3 HEV strain (JE03-1760F/P10), we confirmed the efficacy of these drugs, when used alone or in combination with existing anti-HEV drugs. This underscores their significance in the quest for an effective anti-HEV treatment. In the present review, we discuss the development of the three reporter systems, their applications in drug screening, and their potential to advance our understanding of the incompletely elucidated HEV life cycle.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Hepatitis E virusHepatitis EHumansDrug Evaluation, PreclinicalAntiviral AgentsRibavirinVirus Replication

Stichwörter der Autor:innen

GLucHiBiTdrug screeninghepatitis E virusnanoKAZvirus life cyclevirus reporter system

Substanzen

Antiviral AgentsRibavirin

Autor:innen und Institutionen

  • Division of Virology, Department of Infection and Immunity, Jichi Medical University School of Medicine, 3311-1 Yakushiji, Shimotsuke 329-0498, Tochigi, Japan.
  • Laboratory of Membrane Proteins, Research Division for Quantitative Life Sciences, Institute for Quantitative Biosciences, The University of Tokyo, 1-1-1 Yayoi, Bunkyo-ku, Tokyo 113-0032, Japan.

ORCID-Profile: Putu Prathiwi Primadharsini, Shigeo Nagashima, Hiroaki Okamoto

Förderung

  • Japan Society for the Promotion of Science
  • Japan Agency for Medical Research and Development

Zitieren

APA

Primadharsini, P. P., Nagashima, S., Nishiyama, T., & Okamoto, H. (2023). Three Distinct Reporter Systems of Hepatitis E Virus and Their Utility as Drug Screening Platforms. Viruses. https://doi.org/10.3390/v15101989

Vancouver

Primadharsini PP, Nagashima S, Nishiyama T, Okamoto H. Three Distinct Reporter Systems of Hepatitis E Virus and Their Utility as Drug Screening Platforms. Viruses. 2023. doi:10.3390/v15101989

BibTeX
@article{Primadharsini2023,
  author = {Primadharsini, Putu Prathiwi and Nagashima, Shigeo and Nishiyama, Takashi and Okamoto, Hiroaki},
  title = {Three Distinct Reporter Systems of Hepatitis E Virus and Their Utility as Drug Screening Platforms},
  journal = {Viruses},
  year = {2023},
  doi = {10.3390/v15101989}
}
Kostenlos starten →